Research and Markets has announced the addition of the "TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016" report to their offering.
TAR DNA-Binding Protein 43 (TDP-43) pipeline target constitutes close to 7 molecules, out of which approximately 7 molecules are developed by companies. The report "TAR DNA-Binding Protein 43 - Pipeline Review, H1 2016" outlays comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
TAR DNA-Binding Protein 43 (TDP-43) TAR DNA-binding protein 43 or TDP-43 is a protein encoded by the TARDBP gene. It is involved in the regulation of CFTR splicing, microRNA biogenesis, apoptosis and cell division. It represses HIV-1 transcription by binding to the HIV-1 long terminal repeat. It stabilizes the low molecular weight neurofilament mRNA through a direct interaction with the 3' UTR. The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 3 respectively.
Furthermore, this report also reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/ldvbhm/tar_dnabinding
Related Topics: Central Nervous System Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005766/en/Business Wire
Last updated on: 31/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.